Document is current
Any future updates will be listed below
-
Authors
Bollo, Luca https://orcid.org/0000-0002-3673-2030
Caputo, Francesca https://orcid.org/0000-0002-6734-0523
Paolicelli, Damiano https://orcid.org/0000-0002-8645-1763
Trojano, Maria https://orcid.org/0000-0002-6329-8946
Iaffaldano, Pietro https://orcid.org/0000-0003-2308-1731
- License Information
-
More Information
Article History
Received: 27 February 2022
Accepted: 8 April 2022
First Online: 29 April 2022
Declarations
:
: MT has served on Scientific Advisory Boards for Biogen, Novartis, Roche, Merck, and Genzyme; has received speaker honoraria from Biogen Idec, Merck, Roche, Teva, Sanofi-Genzyme, and Novartis; and has received research grants for her Institution from Biogen Idec, Merck, Roche, and Novartis. PI has served on scientific advisory boards for Biogen Idec and has received funding for travel and/or speaker honoraria from Sanofi-Aventis, Biogen Idec, Teva, and Novartis. DP received advisory board membership, speaker’s honoraria, travel support, research grants, consulting fees, or clinical trial support from Almirall, Bayer Schering, Biogen, Celgene, Excemed, Genzyme, Merck, Mylan, Novartis, Sanofi, Roche, and Teva. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
: This article does not contain any studies with human participants or animals performed by any of the authors.
: The patient has consented to the submission of the case report to the journal and she signed an informed consent regarding publishing her clinical data. The adverse event was reported to the Italian Medicines Agency (AIFA).
